NCT01116648 2026-03-05
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
25 trialsNCT02068794 2025-11-18
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Mayo Clinic
Phase 1/2 Active not recruiting
NCT03519178 2025-11-14
A Study of PF-06873600 in People With Cancer
Pfizer
Phase 1/2 Terminated
NCT01012817 2025-09-15
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04611126 2025-08-12
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Herlev Hospital
Phase 1/2 Terminated
NCT04019288 2025-06-11
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02713386 2025-05-25
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
Phase 1/2 Completed
NCT04442126 2025-05-23
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
Phase 1/2 Terminated
NCT05261490 2024-11-19
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
Phase 1/2 Terminated
NCT02606305 2024-06-14
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
Phase 1/2 Completed
NCT03311334 2024-04-18
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT01962948 2024-03-26
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT02915523 2024-01-10
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT01482715 2023-06-09
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
pharmaand GmbH
Phase 1/2 Completed
NCT02166905 2023-02-24
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT02657889 2022-12-01
TOPACIO
Tesaro, Inc.
Phase 1/2 Completed
NCT03029598 2022-07-26
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 1/2 Completed
NCT01312389 2021-11-15
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT01035658 2021-10-28
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
SCRI Development Innovations, LLC
Phase 1/2 Terminated
NCT03480750 2020-11-10
Trientine
National Cheng-Kung University Hospital
Phase 1/2 Completed
NCT00436501 2019-02-26
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00910000 2018-09-10
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT01188876 2018-01-19
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Massachusetts General Hospital
Phase 1/2 Completed
NCT00182767 2016-03-10
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00421889 2015-07-28
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
Valerio Therapeutics
Phase 1/2 Completed